Investigations Concerning Hydrolysis and Stabilization of Antiradiation Compounds
Abstract
This report contains results of the following studies: Encapsulation of ethiofos (WR 2721) for use as oral dosage forms. In vitro evaluation of the most promising samples. Development of analytical methodology for the active species. Preliminary pharmacokinetic results of in vivo studies. This report covers studies conducted on S-2-(3-aminopropylamino)ethyl phosphorothioic acid, ethiofos (WR 2721), over the period January 16, 1983 through January 13, 1984. The most significant results obtained during this report period are following. Plasma HPLC assay methods have been developed for ethiofos over the range of 0. 05 micrograms/mL to >1000 micrograms/mL. The improved ethiofos assay method has been used successfully in two dosing experiments with beagle dogs. An HPLC plasma assay method has been developed for WR 1065 over the range of 1 microgram/mL to >500 micrograms/mL. WR 1065 disappears quickly in dog plasma even at -78 C. Methods to stabilize the plasma samples have been investigated and some appear very promising. The WR 1065 assay method has been used in a preliminary ethiofos dosing study with a beagle dog.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1984
- Accession Number
- ADB094846
Entities
People
- C. W. Lew
- D. J. Mangold
- E. P. Mcgovern
- N. F. Swynnerton
- T. M. Ludden
Organizations
- Southwest Research Institute